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Distinct Ontogeny of Glucocorticoid and Mineralocorticoid
Receptor and 11b-Hydroxysteroid Dehydrogenase Types I and II
mRNAs in the Fetal Rat Brain Suggest a Complex Control of
Glucocorticoid Actions
Rochellys Diaz, Roger W. Brown, and Jonathan R. Seckl
Molecular Medicine Centre, Western General Hospital, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom
Glucocorticoids (GCs) act via intracellular mineralocorticoid
(MR) and glucocorticoid receptors (GR). However, it has re-
cently been recognized that GC access to receptors is deter-
mined by the presence of tissue-specific 11b-hydroxysteroid
dehydrogenases (11b-HSDs) that catalyze the interconversion
of active corticosterone and inert 11-dehydrocorticosterone.
11b-HSD type 1 (11b-HSD1) is a bidirectional enzyme in vitro
that acts predominantly as a reductase (regenerating cortico-
sterone) in intact neurons. In contrast, 11b-HSD type 2 (11b-
HSD2) is a higher affinity exclusive dehydrogenase that ex-
cludes GCs from MR in the kidney, producing aldosterone-
selectivity in vivo. We have examined the ontogeny of 11b-HSD
mRNAs and enzyme activity during prenatal brain development
and correlated this with GR and MR mRNA development. These
data reveal that (1) 11b-HSD2 mRNA is highly expressed in all
CNS regions during midgestation, but expression is dramati-
cally reduced during the third trimester except in the thalamus
and cerebellum; (2) 11b-HSD2-like activity parallels closely the
pattern of mRNA expression; (3) 11b-HSD1 mRNA is absent
from the CNS until the the third trimester, and activity is low or
undectectable; and (4) GR mRNA is highly expressed through-
out the brain from midgestation, but MR gene expression is
absent until the last few days of gestation. High 11b-HSD2 at
midgestation may protect the developing brain from activation
of GR by GCs. Late in gestation, repression of 11b-HSD2 gene
expression may allow increasing GC activation of GR and MR,
permitting key GC-dependent neuronal and glial maturational
events.
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A wealth of studies suggest that early life environment influences
brain development and subsequent adult CNS function. In par-
ticular, maternal stress during pregnancy produces persisting
neuroendocrine and behavioral abnormalities in the offspring,
altering motor development, enhancing emotionality, amplifying
amphetamine self-administration, and increasing locomotor re-
sponses to novelty (Ader and Blackman, 1971; Barlow et al., 1978;
Demeniere et al., 1992). Prenatal stress also modifies the offspring
hypothalamic–pituitary–adrenal (HPA) axis, a key neuroendo-
crine effector of the stress response (Meaney et al., 1996; Wein-
stock et al., 1997). Clinically, HPA axis dysregulation is associ-
ated with psychiatric syndromes including depression, eating
disorders, anxiety, and age-related cognitive dysfunction (Hols-
boer et al., 1994; Seckl and Olsson, 1995), and neurodevelopmen-
tal factors may be etiologically important in several of these
syndromes. Indeed, HPA axis activity in elderly men correlates
with birth weight, which is a measure of the prenatal environment
(Phillips et al., 1997). Together, these data suggest that maternal
stress during pregnancy could increase the vulnerability of the
offspring to behavioral brain-related pathologies. These changes
could be mediated by in utero exposure of the developing brain to
elevated levels of maternal glucocorticoids (GCs) secreted during
HPA axis activation by stress that can cross the placenta barrier
and reach the developing fetal brain (Zarrow et al., 1970). Pre-
natal GC exposure permanently “programs” several central func-
tions, including dopamine sensitivity (Diaz et al., 1997), seroton-
ergic activity (Slotkin et al., 1996), and HPA axis parameters
(Levitt et al., 1996).
GC actions are primarily mediated via intracellular glucocor-
ticoid receptor (GR) and mineralocorticoid receptor (MR) (de
Kloet, 1991). MRs bind both physiological GCs (cortisol, corti-
costerone) and mineralocorticoids (aldosterone) with an equally
high affinity (Kd , .0.5 nM), whereas GR preferentially binds
cortcosterone but with a lower affinity (2.5–5.0 nM). However, it
has recently been recognized that the effects of GCs on their
target cells are not only regulated by plasma steroid levels,
corticosteroid-binding globulin (CBG), and receptor density, but
also by the presence of 11b-hydroxysteroid dehydrogenases (11b-
HSDs) (Seckl, 1997a). 11b-HSDs catalyze the interconversion of
physiological GCs (cortisol and corticosterone) and inert 11-keto
metabolites (cortisone and 11-dehydrocorticosterone). Recently
two isozymes have been characterized, encoded by distinct genes
(White et al., 1997). 11b-HSD type 1 (11b-HSD1) is a widely
expressed NADPH-dependent oxidoreductase (Agarwal et al.,
1989). In intact cells, including neurons, 11b-HSD1 is a predom-
inant 11b-reductase that regenerates active corticosterone from
inert 11-dehydrocorticosterone (Hundertmark et al., 1995; Jamie-
son et al., 1995; Rajan et al., 1996). In contrast, 11b-HSD type 2
(11b-HSD2) is a nicotinamide adenine dinucleotide (NAD)-
dependent high-affinity isozyme and is an exclusive 11b-
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dehydrogenase that rapidly inactivates GCs, thus protecting oth-
erwise nonselective MR from GCs in aldosterone target tissues
(e.g., distal nephron) (White et al., 1997). Administration of
11b-HSD inhibitors during rat pregnancy adversely programs
peripheral systems, producing hypertension and hyperglycemia in
adult offspring (Lindsay et al., 1996a,b). Although 11b-HSD
bioactivity has been previously demonstrated in adult and peri-
natal brain (Moisan et al., 1990; Lakshmi et al., 1991; Moisan et
al., 1992), these studies predated the identification of the two
isozymes and their distinct reaction directions. We therefore
investigated the detailed ontogeny of 11b-HSD mRNAs and
enzyme activity and correlated this with GR and MR expression
during rat brain prenatal development to identify potential time-
and locus-dependent “windows” for GC action.
MATERIALS AND METHODS
Subjects. Female Sprague Dawley rats were put into the home cages of
individually housed male rats at 5:00 P.M. and were removed the next
morning. Coitus was determined by vaginal smear. The morning of sperm
detection was designated embryonic day 0.5 (E0.5). At least two dams
were decapitated at each of successive gestational days between 11:00
A.M. and 12:00 P.M., and the embryos were removed by cesarean
section. Embryos aged E11.5–E14.5 were immediately frozen in toto into
a 220°C isopentane bath. From E15.5, embryos were decapitated before
freezing. All tissues were stored at 280°C.
11b-HSDs and GR and MR probes. The MR cRNA was prepared from
a 513 bp EcoRI fragment of rat mineralocorticoid receptor cDNA (rep-
resenting parts of the steroid-binding domain and 39 untranslated region)
and was subcloned into the vector pGEM4 (Arriza et al., 1988). The
plasmid was linearized with either HindIII or EcoRI and used as a
template for SP6 or T7 RNA polymerase to generate the antisense and
sense, respectively. The GR cRNA was prepared from a 674 bp PstI–
EcoRI fragment of the rat glucocorticoid receptor cDNA corresponding
to the 39 portion of the coding region (steroid-binding domain) and was
subcloned into the vector pGEM3 (Seckl et al., 1990). The antisense and
sense probes were generated using AvaI (T7) and EcoRI (SP6), respec-
tively. The 11b-HSD2 was prepared from a 613 bp fragment obtained by
reverse transcription-PCR from rat kidney RNA using primers to con-
served regions of the 11b-HSD2 and subcloned into a pGEM-T vector
(Leckie et al., 1995). The antisense and sense probes were generated
using NcoI (SP6) and NotI (T7), respectively. The 11b-HSD1 was pre-
pared from a 1.2 kb EcoRI fragment of the rat 11b-HSD1 cDNA and
subcloned into the vector pBluescript SKII (Agarwal et al., 1989). The
antisense and sense probes were generated using StyI (T3) and PstI (T7),
respectively. 35S-Uridine 59-triphospate (UTP)-labeled RNA antisense
and sense probes were transcribed in vitro using the appropriate template
and phage RNA polymerase, purified using Nensorb Columns (DuPont,
Billerica, MA), and checked on denaturing acrylamide gels.
In situ hybridization. Sagittal (in relation to the head) 20 mm cryostat
sections were thaw-mounted on 3-aminopropyltriethoxysilane-coated
slides and stored at 280°C. Tissue sections were fixed, prehybridized,
hybridized (hybridization was made with ;3 3 10 6 cpm/section 35S-
UTP-labeled RNA probe at 50°C for 12–14 hr), and washed essentially as
described previously (Belluardo et al., 1997). After RNase A washing,
treated slides were hydrated, dried, placed against b-Max (Hyperfilm
b-film; Amersham, Arlington Heights, IL), and stored at room temper-
ature for 1–2 weeks. Films were developed in D19 developer for 2 min
and fixed in a 1:5 dilution of Amfix fixative for 2 min. Adjacent sections
were stained with cresyl violet to allow neuroanatomical localization of
the specifically labeled CNS regions (data not shown). The atlas of
prenatal rat brain development by Altman and Bayer (1995) was con-
sulted. Nonspecific hybridization was determined by incubating adjacent
sections with the respective 35S-UTP-labeled sense cRNA probe for the
above cDNAs under identical conditions. Nonspecific background was
very low in all sections analyzed from all fetal ages (data not shown).
11b-HSD activity. 11b-Reductase and 11b-dehydrogenase activity was
determined from homogenates of rat brain tissue at ages E12.5, E14.5,
E17.5, and E20.5. The assays were performed according to a standard
protocol described elsewhere (Brown et al., 1996) and included 100 mM
cofactor (NAD or NADP for dehydrogenase or NADPH for reductase)
and 12 nM final 3H-labeled steroid ([ 3H]corticosterone for dehydroge-
nase and [ 3H]11-dehydrocorticosterone for reductase). In addition, we
assayed samples of liver (for reductase) and placenta (for dehydroge-
nase) from each fetus as an internal control to demonstrate that 11b-
HSD1 and 11b-HSD2 were detectable in tissues outside the brain at each
gestational age. Preliminary experiments showed that 0.25 mg/ml ho-
mogenate protein was the optimal concentration in the curve describing
the relationship between protein concentration and enzyme activity. All
assays used 0.25 mg/ml; two time points (10 and 40 min) were used for
dehydrogenase and three time points were used for reductase (10, 40, and
90 min). Because the results for the dehydrogenase were similar at the
two time points, only the 10 min data are presented.
Corticoterone levels. Plasma corticosterone levels were measured by
radioimmunoassay at ages E12.5, E14.5, E17.5, and E20.5, as described
previously (Holmes et al., 1997), but modified for microtiter scintillation
plate assay (SPA, Amersham). Briefly, the incubation volume was 120 ml,
consisting of 20 ml of 103 diluted plasma, 50 ml of antiserum (1:10,000)/
[ 3H]corticosterone mix (12,000 cpm/tube 1,2,6,7-[ 3H]corticosterone,
Amersham), and 50 ml of SPA beads. After an overnight incubation at
room temperature, the microtiter plates were counted on a Wallac
microbeta liquid scintillation counter.
RESULTS
Ontogeny of 11b-HSD2 mRNA
High 11b-HSD2 gene expression is observed throughout the CNS
neuroepithelium, including the pituitary gland primordium at
E11.5 (Fig. 1) (brain areas are labeled in Figs. 1–5). 11b-HSD2
mRNA expression remains high until E13.5. By E14.5, the expres-
sion starts to decrease in the neocortex, pallidal area, and spinal
cord (data not shown). By E15.5, 11b-HSD2 expression is re-
stricted to several discrete areas that include thalamus (although
Fig. 1 only shows anterior and posterior areas, its expression is
more widely distributed), cerebellum, midbrain (superior collicu-
lus differentiating field), various pontine regions (e.g., locus co-
eruleus and precerebellar area), septum, hypothalamus (preoptic
area and anterior and ventral hypothalamus), medulla, pallidum
(data not shown), and strianuclear complex. At E16.5, 11b-HSD2
mRNA expression is still high in several areas that include the
straitum, midbrain (superior and inferior tectal neuroepithelium,
inferior colliculus, and pretectum), thalamus, preoptic area, and
ventral hypothalamus (e.g., arcuate nucleus), cerebellum (exter-
nal granular layer), and low to moderate in septum (data not
shown) (Fig. 3). 11b-HSD2 mRNA expression remains similar
from E16.5 until E19.5, when expression ceases in the midbrain
and is low in the septum. However, 11b-HSD2 mRNA is still
present in preoptic area and ventral hypothalamus (e.g., arcuate
nucleus). By E20.5, 11b-HSD2 gene expression is restricted to the
external granular layer of the cerebellum, precerebellar area, and
thalamus, and at E22.5 (the day of birth) 11b-HSD2 mRNA is
only found in the external granular layer of the cerebellum and
thalamus (Figs. 3, 5).
Ontogeny of 11b-HSD1 mRNA
11b-HSD1 mRNA expression is clearly very low or absent before
E15.5 (Figs. 1, 3). Moderate 11b-HSD1 mRNA expression is first
seen at E16.5 in hippocampus, precerebellar area, and medulla
(data not shown). From E17.5 to E22.5, there is a gradual in-
crease in expression throughout the CNS, including the pituitary
gland primordium. At E17.5, there is also expression in the
tegmental area (data not shown). The pattern of 11b-HSD1 gene
expression is similar between E18.5 and E22.5 (date of birth)
(Figs. 3, 5). High 11b-HSD1 mRNA expression is observed in
thalamus, neocortex, hypothalamus (particularly in the anterior
and ventral parts), pituitary gland (primordium), brainstem (both
pons and medulla areas), dorsal periaqueductal gray area, teg-
mental area, spinal cord, and hippocampus (Fig. 6).
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Figure 1. Expression of 11b-HSD type 2 and 11b-
HSD type 1 in the rat brain from E11.5 to E15.5.
Results of in situ hybridization for 11b-HSD TYPE 2
and 11b-HSD TYPE 1 are shown from lef t to right,
respectively, for each gestation. The following are la-
beled in Figures 1–5: 1, extraembryonic membrane; 2,
hippocampal (Ammon’s horn) and subicular regions; 3,
neocortex; 4, septum; 5, liver; 6, dorsal mesencephalon;
7, pontine area; 8, intermediate, mammillary, and pos-
terior hypothalamic areas; 9, hypothalamus and ante-
rior hypothalamus; 10, tegmental area; 11, intermedi-
ate thalamus; 12, medulla; 13, spinal cord; 14, dorsal
diencephalon; 15, cerebellum; 16, pituitary; 17, uterine
wall; 18, taenia tecta; 19, indesium griseum; 20, cingu-
late cortex; 21, lamina terminalis; 22, epithalamus; 23,
pretectum; 24, ventral hypothalamus; 25, preoptic area;
26, thalamus; 26a, posterior thalamus and epithalamus;
26b, thalamus and anterior-medial area; 27, mammill-
ary area; 28, posterior hypothalamus; 29, ventral isth-
mal area; 30, inferior colliculus; 31, superior colliculus;
32, dorsal isthmal area; 33, precerebellar area; 34, basal
ganglia and strionuclear area; 35, pallidum; 36, arcuate
nucleus and ventral medial hypothalamus; 37, posterior
thalamus; 38, anterior thalamus; 39, olfactory bulb; 40,
locus coerulus; 41, anterior pontine area; 42, posterior
pontine area; 43, dorsal raphe; 44, pineal gland; 45,
choroid plexus and lateral ventricle; 46, skin; 47, pre-
cerebellar area and above choroid plexus; and 48, dor-
sal periaqueductal gray and superior colliculus.
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Figure 2. Expression of GR and MR in the rat brain
from E11.5 to E15.5. Results of in situ hybridization
for GR and MR are shown from lef t to right, respec-
tively, for each gestation. For labeling of regions see
text of Figure 1.
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Figure 3. Expression of 11b-HSD type 2 and 11b-HSD type 1 in the rat brain from E16.5 to E20.5. Results of in situ hybridization for 11b-HSD TYPE
2 and 11b-HSD TYPE 1 are shown from lef t to right, respectively, for each gestation. For labeling of regions see text of Figure 1.
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Figure 4. Expression of GR and MR in the rat brain from E16.5 to E20.5. Results of in situ hybridization for GR and MR are shown from lef t to right,
respectively, for each gestation. For labeling of regions see text of Figure 1.
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11b-HSD activity
NAD1-dependent 11b-dehydrogenase activity (11b-HSD2) is
clearly detectable in whole brain and placental extracts at all
gestational ages examined (Fig. 7). 11b-HSD2 activity in the
brain is high at E12.5 and E14.5 but by E17.5 is dramatically
reduced to ;24% of the levels observed during midgestation.
11b-HSD2 enzyme activity remains low at E20.5. The overall
pattern of placental 11b-HSD2 activity was similar to that in the
brain. In contrast, NADP1-dependent 11b-dehydrogenase (11b-
HSD1) was very low in brain extracts at all gestational ages (Fig.
7). NADPH1-dependent 11b-reductase (11b-HSD1) was unde-
tectable in brain extracts at all ages. However, in the liver there
was an increase in 11b-reductase activity at E17.5 (10.65 6
1.95%) and E20.5 (29.05 6 0.75%) (90 min incubation).
Ontogeny of GR mRNA
GR mRNA expression is first seen at E12.5 in the neuroepithe-
lium (high levels are already present in the periphery, e.g., liver
1 d earlier) (Fig. 2). At this stage, there is an overall increase in
GR mRNA expression throughout the body. In the CNS, high
expression is only seen in the pons (mainly posterior area),
medulla (both ventral and dorsal parts), anterior hypothalamus,
spinal cord, and pituitary gland (primordium). At E13.5, high
expression of GR mRNA is also detected in septum, preoptic
area, and hippocampus (data not shown). By E14.5, GR mRNA
expression dramatically increases in the ventral part of the spinal
cord and to a lesser extent in the thalamus. GR mRNA is also
seen in the ventral isthmal area. By E15.5, there is increased GR
mRNA expression in neocortex, olfactory bulb, precerebellar
area, cerebellum, choroid plexus, tegmentum, and basal glanglia
(striatal and pallidal neuroepithelia). In contrast, GR mRNA
expression dramatically decreases in spinal cord and moderately
decreases in the thalamus and septum. At E16.5, GR gene ex-
pression appears in the locus coeruleus and superior colliculus
and continues to increase in septum, olfactory bulb, neocortex,
and hippocampus (Fig. 4). Expression of GR mRNA is similar at
E17.5. At E19.5, GR mRNA expression is also seen in the pineal
gland and periaqueductal gray area. Moreover, there is an in-
crease of GR mRNA in cerebellum. This pattern of expression
persists until E22.5. However, during this period there is a clear
increase in the level of GR expression throughout all the CNS-
differentiating fields (Figs. 4, 5).
Ontogeny of MR mRNA
MR mRNA expression is clearly absent in the CNS during
midgestation (Fig. 2). Moderate MR mRNA expression is first
seen at E15.5 in pituitary gland (primordium), brainstem (medul-
la area), facial motor nucleus, tegmentum, and neuroepithelium
of the septum and pallidum (data not shown). At E16.5, low
expression can also be detected in hippocampal neuroepithelium.
MR mRNA expression moderately increases by E17.5 and is first
seen in the anterior hypothalamus (Fig. 4). At E19.5, MR mRNA
expression dramatically increases in hippocampus, septum, rhi-
nencephalon (data not shown), anterior hypothalamus, periaque-
ductal gray area, and brainstem (pontine and medulla) neuroep-
ithelium. There is also clear MR mRNA expression in the
amygdala and piriform cortex. This pattern of expression persists
until E22.5 (see Fig. 6).
Figure 5. Expression of GR, MR, 11b-HSD TYPE 2, and 11b-HSD TYPE 1 mRNAs in the rat brain at E22.5. For labeling of regions see text
of Figure 1.
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Plasma corticosterone levels
It was not possible for plasma corticosterone levels to be assayed
at E12.5 because of insufficient blood volume. At E14.5, cortico-
sterone levels were ,3 nM. On E17.5 there was a clear increase in
corticosterone levels (161 nM). By E20.5 corticosterone levels
increased further to double the levels observed on E17.5 (333
nMol). The intra-assay variation was well ,10%, and the figures
were consistently indicated by different dilutions of the plasma
that was pooled from at least 5 fetuses (12 for E14.5).
DISCUSSION
This study represents the first description of the ontogeny of
11b-HSD isozymes during prenatal rat brain development. The
results clearly demonstrate a distinct pattern of expression for
each enzyme. 11b-HSD2, which potently inactivates GCs, is
widely expressed in the neuroepithelium until the beginning of
the third trimester, when the expression falls dramatically. In
contrast, 11b-HSD1 mRNA (encoding an enzyme that largely
reactivates GCs in vivo) is low or absent until late gestation.
There are also precise temporal and spatial changes in expression
of GR, and later MR, during prenatal rat brain development. The
data clearly show potential time- and locus-dependent windows
for adrenal steroid hormone action on fetal brain development via
changes in both receptor expression and enzymatic control of GC
access to receptors.
GR and MR expression in fetal brain
The data confirm and extend previous findings on corticosteroid
receptor gene expression in fetal brain (Cintra et al., 1993; Rene et
al., 1994; Yi et al., 1994; Kitraki et al., 1996). In agreement with
Cintra et al. (1993), GR mRNA was found highly expressed in the
neuroepithelium of multiple brain areas (including hippocampus,
cerebellum, hypothalamus, raphe nuclei, locus coeruleus, and ol-
factory bulb) during the last trimester of gestation. In addition, we
found GR mRNA expression within the septal, pallidal, and strio-
nuclear complex neuroepithelia during this period. The present
data also extend to earlier stages of development to reveal high GR
mRNA expression during midgestation (starting at E12.5). Previ-
ous findings have demonstrated that GR mRNA is translated to an
adult-like protein in fetal tissue, suggesting that GR is functional
and participates in developmental processes such as cell birth,
migration, differentiation, and maturation (Meaney et al., 1985).
Another important observation is that toward the end of the third
trimester GR mRNA expression increases throughout the brain,
including within the differentiating fields, which coincides with the
activation of the fetal HPA axis (Milkovic et al., 1973). These
observations support the notion that endogenous GCs acting via
GR may play a role in differentiation and maturational events
during late fetal brain development. GCs may promote the transi-
tion between a proliferative and a differentiating stage by directly
inhibiting cell division as well as activating the expression of
specific genes characteristic of the differentiated mature pheno-
type. Indeed, GCs have been reported in vitro to decrease the rate
of cell proliferation by preventing progression through the cell
cycle and extending the G1 phase or G2 and M phases in non-
neuronal cells (Fanger et al., 1987; Vintermyr et al., 1989;
Hatakeyama et al., 1991; Sanchez et al., 1993).
Figure 6. Expression of GR, MR, 11b-HSD TYPE 2, and 11b-HSD TYPE 1 mRNAs in the rat hippocampus at E22.5. The following regions are labeled
in the figure: striatum (st); lateral ventricle (lv); hippocampus (hr); dorsal hippocampus (dh); ventral hippocampus (vh); and piriform cortex ( pc). Arrows
indicate skin tissue.
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In contrast to widespread GR gene expression, MR mRNA
expression was confined to the neuroepithelium of the septal–
hippocampal system and a few discrete areas of the anterior
hypothalamus, pituitary, deep layers of the superior colliculus,
piriform cortex, and brainstem. Also in contrast to GR mRNA
expression, MR mRNA expression was very low or absent until
the last 3 d of gestation, when it became more prominent in the
hippocampus and lateral septum. Indeed, at the end of gestation,
MR was higher than GR mRNA expression in the hippocampus
and septum, confirming previous observations (Bohn et al., 1994).
MR binding sites have been reported in both neurons and glia in
fetal hippocampal cell cultures (Bohn et al., 1991), suggesting that
MR mRNA is likely to be translated. Physiological MR agonists,
such as aldosterone, affect neuronal and glial cell birth and death
rates in early postnatal dentate gyrus (see Gould and Cameron,
1996), and MR, as well as GR, may regulate similar processes in
the developing fetal brain. The mechanisms of MR induction late
in gestation are unknown. Possible factors include (1) activation
of the fetal HPA axis, although MR is slightly regulated by GCs
during adult life (Seckl, 1997a), and dexamethasone in the last
trimester reduces MR gene expression in adult life (Levitt et al.,
1996); and (2) more likely, the contemporaneous development of
neurotransmitter inputs (e.g., 5-hydroxytryptamine) that potently
controls hippocampal GR and MR expression in perinatal and
adult life (see Meaney et al., 1996).
11b-HSD expression in fetal brain
Previous studies suggested that the high 11b-HSD bioactivity in
whole fetal brain extracts (Burton et al., 1968) is comparable to
the levels in the adult kidney. Limited human studies suggest that
high 11b-HSD is confined to early or midgestation and falls in the
third trimester in many tissues, including brain (Murphy, 1981;
Stewart et al., 1994). Our results demonstrate the predominance
of the NAD-dependent 11b-HSD2 isozyme throughout the midg-
estation fetal rat brain, with 11b-dehydrogenase bioactivity par-
alleling the pattern of 11b-HSD2 mRNA expression. The high
levels of 11b-HSD2 in the neuroepithelium during midgestation
are likely to profoundly attenuate GC effects during the stage of
CNS development. Similarly, abundant 11b-HSD2 in placenta
during midgestation is thought to protect the fetus from the
deleterious effects of high maternal GCs by ensuring that most
maternal glucocorticoids are inactivated on crossing to the fetus
(see Seckl, 1997b). Low plasma corticosterone levels in the fetus
during midgestation may reflect rapid inactivation of GCs by
widespread 11b-HSD2 in placenta and fetal tissues. However,
there is no evidence available indicating that 11b-HSD2 is so
effective as to abolish GR activation by GCs during this period.
Thus, further studies are required to determine the relationship
between brain corticosterone levels, GR occupancy, and 11b-
HSD2 activity during early fetal development.
The present data do not support the notion that 11b-HSD2
protects MR during brain development, because MR mRNA is
not expressed when 11b-HSD2 is most abundant. Given that GR
gene expression is seen from early stages of development, and
exposure of the developing fetus to excess GCs can result in fetal
death (Yang et al., 1969), 11b-HSD2 may be protecting the
developing CNS from the adverse effects of endogenous GCs
acting via GR. Although severe brain abnormalities are not
prominent in humans with the syndrome of apparent mineralo-
corticoid excess caused by deleterous mutations of the 11b-HSD2
gene (Mune et al., 1995; Wilson et al., 1995), more subtle CNS
abnormalities have not been sought in these exceptional patients
who rarely survive childhood. certainly, poor 11b-HSD2 substrate
GCs, such as dexamethasone, have distinct programming effects
on CNS maturation before birth (Levitt et al., 1996; Slotkin et al.,
1996). It is also conceivable, although unlikely, that the function
of 11b-HSD2 differs during development, perhaps catalyzing
metabolism of putative alternative 11b-hydroxysteroid substrates.
The mechanism downregulating 11b-HSD2 in fetal brain at
midgestation is unclear, although widespread silencing may be
related to C and G-rich sequences reported in the 59 region of the
11b-HSD2 gene (Brown et al., 1996).
Recently, Rajan et al. (1996) demonstrated 11b-HSD1 gene
expression and activity in fetal hippocampal cells in culture. The
present work confirms this observation and also demonstrates
Figure 7. 11b-Dehydrogenase activity from homogenates of rat brain
tissue ( A) and placenta ( B) at ages E12.5, E14.5, E17.5, and E20.5.
Cosubstrates were added at 100 mM. Note the predominant NAD 1-
dependent reaction, typical of 11b-HSD2.
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11b-HSD1 gene expression in other brain regions, including the
thalamus, hypothalamus, pituitary, brainstem, and cortex. How-
ever, 11b-HSD1 gene expression was much lower than that of
11b-HSD2 mRNA and was restricted to late gestation, when
11b-HSD2 mRNA expression was declining. Interestingly, both
11b-HSD1 and MR expression increase after fetal adrenocortical
activation has occurred and circulating fetal corticosterone levels
are rising (Dupouy et al., 1975; Milkovic et al., 1973). Previous
studies have demonstrated that dexamethasone administration, or
stress, increase 11b-HSD1 mRNA expression and enzyme bioac-
tivity in the adult rat hippocampus (Low et al., 1994). Similar GC
induction of 11b-HSD1 occurs in primary rat hippocampal cul-
tures from E18 (Rajan et al., 1996). Moreover, there is a putative
glucocorticoid response element in the promoter of the rat 11b-
HSD1 gene (Voice et al., 1996). It is thus possible that the rise in
fetal corticosterone levels during the last part of the third trimes-
ter may induce 11b-HSD1 mRNA expression in fetal brain. 11b
reduction is clearly the predominant reaction in intact cells from
a variety of tissues, including brain, liver, and lung (Hundertmark
et al., 1995; Jamieson et al., 1995; Rajan et al., 1996). However,
any physiological role for the 11b-HSD1 in modulating exposure
of the developing brain to GCs (either protecting against or
increasing exposure to GCs) remains unclear, because 11b-HSD1
activity is barely, if at all, detected in the rat fetal brain. Because
these studies were performed in homogenates of whole fetal
brain, it is possible that regional differences in 11b-HSD1 activity
could have been masked. Thus, at this early point in the investi-
gation, the presence of 11b-HSD1 in the fetal brain seems likely,
but requires further investigation.
The importance of the intrauterine environment has been
emphasized by studies showing that prenatal stress exerts long-
lasting effects on a variety of neuroendocrine and behavioral
parameters (see Weinstock et al., 1997). It has been postulated
that these changes could be mediated by direct effects on the
developing brain after in utero exposure to elevated levels of
maternal or fetal GCs. Our data suggest exquisite time and re-
gion-specific windows for GC action within the developing CNS.
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